FDA has released the draft guidance Software as a Medical Device (SaMD): Clinical Evaluation with the intention of “establishing the scientific validity, clinical performance, and analytical validity for a SaMD,” according to an agency release. The draft aims to provide globally harmonized, risk-based principles of when and what type of clinical evaluation is appropriate for an SaMD, according to FDA.
“Global regulators expect that clinical evaluation and the evidence generated for a SaMD have the same scientific level of rigor that bis commensurate with the risk and impact of the SaMD, to demonstrate assurance of safety, effectiveness and performance. SaMD however is unique in that it operates in a complex highly connected-interactive socio-technical environment in which frequent changes and modifications can be implemented more quickly and efficiently. Development of SaMD is also heavily influenced by new entrants unfamiliar with medical device regulations and terminology developing a broad spectrum of applications.” – SaMD: Clinical Evaluation guidance document excerpt
The 46-page document was put together with the guidance of the International Medical Device Regulators Forum (IMDRF). The Federal Register will receive comments on the draft for the next 60 days.
Related Articles
-
With the increased complexity of devices, a streamlined approach to managing product development risks and documenting compliance is challenging but perhaps more important than ever.
-
How do the latest requirements affect your business?
-
Software verification and validation is a process that produces objective evidence that the software in a medical device has been thoroughly designed, tested, and meets user requirements. The level of depth of testing and documentation is based on overall risk.…
-
Part I in a series of articles that will provide insight into TSP, its applicability to the medical device industry, and how it helps achieve the high level of software quality required for devices.
